Physician profile
John R Culp
NPI 1487646501
$1,840.33
in general payments reported to CMS, 2019-2025
24 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $181 · 2021: $275 · 2022: $297 · 2023: $395 · 2024: $152 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $308.45 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $281.62 | 2020-2025 | |
| Boston Scientific Corporation | $218.07 | 2019-2025 | Watchman Access System |
| Pfizer INC. | $181.02 | 2019-2025 | |
| Medtronic, INC. | $120.01 | 2025 | Micra |
| Amgen INC. | $116.00 | 2019-2023 | Repatha |
| Glaxosmithkline, LLC. | $82.11 | 2022-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $75.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $64.21 | 2020-2021 | |
| Shockwave Medical, INC | $63.18 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.61 | 2022-2023 | Jardiance |
| Alnylam Pharmaceuticals INC. | $40.03 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.40 | 2021-2023 | Camzyos |
| Philips North America LLC | $32.81 | 2022-2023 | |
| Novo Nordisk INC | $22.73 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $22.04 | 2023 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $21.34 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.29 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $19.57 | 2023 | Arcalyst |
| Bardy Diagnostics, INC. | $18.00 | 2020 | |
| Abbott Laboratories | $15.49 | 2021 | |
| Merck Sharp & Dohme LLC | $13.87 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.59 | 2019 | |
| Cardiovascular Systems INC. | $4.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Culp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.